TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03517683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low speed
Description: Speed of intrathecal injection will be 1ml in 15 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High speed
Description: speed of intrathecal injection will be 1ml in 5 seconds
Study: NCT03615469

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
Study: NCT01514188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INNO-206
Description: INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
Study: NCT03452553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
Description: Drug Eluting Beads loaded with chemotherapy
Study: NCT04536740

Intervention type: DEVICE
Group type: OTHER
Intervention: PDT treatment device
Description: All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT treatment device
Description: All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
Study: NCT04169724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation
Description: 10 minutes per day of meditation via the Calm app.
Study: NCT04664595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol Fresenius
Description: final dose of Propofol (mcg/kg) to reach the target effect-site concentration
Study: NCT00028002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally
Study: NCT00312884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomMed Telemonitoring System
Description: The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HomMed Telemonitoring System
Description: The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
Study: NCT04393584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: d1 Irinotecan 180mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: d1-2 5-FU 2450 mg/m² every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: d1-2 5-FU 2450 mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: d1 Leucovorin 200 mg/m² every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: d1 Leucovorin 200 mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: d1 Oxaliplatin 85 mg/m² every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: d1 Docetaxel 50mg/m2 every two weeks
Study: NCT01849835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-rectal to perform the prostate biopsy
Description: the puncture points are at the rectal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans-perineal to perform the prostate biopsy
Description: the puncture points are at the perineal
Study: NCT00809172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: 5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
Study: NCT03914443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg or 360 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg or 360 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg or 360 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg or 360 mg
Study: NCT05405465

Intervention type: DRUG
Intervention: Exposure to golimumab
Description: Retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
Study: NCT03914443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 or 800 mg\^2
Study: NCT01014000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empirical group
Description: Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided approach
Description: Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
Study: NCT03914443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 or 800 mg\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 or 800 mg\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750 or 800 mg\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: 70 or 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: 70 or 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: 70 or 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDDP
Description: 70 or 80 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTX
Description: 70 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTX
Description: 70 mg/m\^2
Study: NCT05112016

Intervention type: PROCEDURE
Intervention: Total mesorectal excision for rectal cancer
Study: NCT03857763

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apatinib,Paclitaxel,Cisplatin,RT
Description: Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
Study: NCT01871896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Suturing to Create Early Satiety
Description: Evaluating the efficacy of endoscopic suturing for weight loss.
Study: NCT00825955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Tablets, Oral, 800 mg, once daily, until disease progression or toxicity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, until disease progression or toxicity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Trans-Arterial Chemo-Embolization (TACE) Therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Trans-Arterial Chemo-Embolization (TACE) Therapy
Study: NCT04652336

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Comparator arm - will receive standard laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ligamentum teres cardiopexy with sleeve gastrectomy
Description: experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
Study: NCT03677687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Physical Activity
Description: The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
Study: NCT04649203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
Description: The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Study: NCT03699787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphomotor intervention program
Description: The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
Study: NCT03615755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
Study: NCT03047148

Intervention type: OTHER
Intervention: Data mining from records
Description: The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.

Intervention type: OTHER
Intervention: Data mining from records
Description: The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
Study: NCT04387058

Intervention type: DEVICE
Group type: OTHER
Intervention: TIPS
Description: TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
Study: NCT01152164

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
Study: NCT03165721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
Study: NCT01126970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velneperit 400 mg
Description: Velneperit 400 mg q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velneperit 400 mg
Description: Velneperit 400 mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat 120 mg
Description: Orlistat 120 mg t.i.d
Study: NCT01241851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Study: NCT03696264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid intake
Description: Amino acid intake will range between 0.2-3.0g/kg/d
Study: NCT00385268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: 1998 mg/dau fpr 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study: NCT04087421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qufora Irrisedo Cone System
Description: The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol OBA
Description: Rectal suppository. Stimulates the rectum and softens and loosens stool.
Study: NCT04358094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis script
Description: Conversational hypnosis during peripherical veinous catheter set up

Intervention type: OTHER
Group type: OTHER
Intervention: Standard script
Description: Standard script during peripherical veinous catheter set up
Study: NCT02131948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Intranasal spray
Study: NCT03480282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prognosis information and Provider Scripts
Description: An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
Study: NCT01914419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT01943734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information passed on anthropometric assessment
Description: Information passed on worker's anthropometric assessment.
Study: NCT03649321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: 200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
Study: NCT01126970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Description: Orlistat 120 mg t.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat Placebo
Description: Orlistat Placebo t.i.d.
Study: NCT03649321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: 200mg orally starting Cycle 1 day 2 every 21 days or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 25 mg/m\^2 Day 1 /8 every 21 days or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 25 mg/m\^2 Day 1 /8 every 21 days or 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
Study: NCT03972644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic valve replacement
Description: Open heart surgery or transcatheter surgery
Study: NCT01515995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized magnesium sulfate
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
Study: NCT01026701

Intervention type: DRUG
Intervention: bortezomib
Description: injection into a vein 1.3 mg/m2 twice a week for 21 days
Study: NCT01163253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg oral BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg oral BID
Study: NCT01672996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioforminol 160 mgI/mL
Description: Given as s single administration to the subject

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioforminol 200 mgI/mL
Description: Given as a single administration to the subject

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 300 mgI/mL
Description: Given as a single administration to the subject
Study: NCT02819310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI400 Laxative
Description: oral laxative
Study: NCT02454218

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions.